News
MTNB
0.1814
-0.22%
-0.0004
Weekly Report: what happened at MTNB last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at MTNB last week (0408-0412)?
Weekly Report · 04/15 11:22
Weekly Report: what happened at MTNB last week (0401-0405)?
Weekly Report · 04/08 11:27
Matinas BioPharma’s Multi-Million Share Sale and Lock-Up Deal
TipRanks · 04/05 11:12
Matinas Biopharma prices $10 million registered direct offering
Matinas Biopharma prices $10 million registered direct offering. Matinas BioPharma Holdings, Inc. (MTNB) Stock. The company intends to use the net proceeds from the offering for working capital and general corporate purposes. The offering is expected to close on April 5.
Seeking Alpha · 04/03 12:38
MATINAS BIOPHARMA PRICES $10 MILLION REGISTERED DIRECT OFFERING
Reuters · 04/03 12:30
MATINAS BIOPHARMA HOLDINGS INC - FOR PURCHASE AND SALE OF 33.3 MLN SHARES OF COMMON STOCK AND WARRANTS AT A COMBINED OFFERING PRICE OF $0.30 PER SHARE
Reuters · 04/03 12:30
Matinas BioPharma (MTNB) Gets a Buy from Maxim Group
TipRanks · 04/02 14:35
12 Health Care Stocks Moving In Monday's After-Market Session
OpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. Kyverna Therapeutics shares increased by 9.19%. Galecto and Ontrak also gained ground. Gritstone Bio and Aclarion were among the losers in the market.
Benzinga · 04/01 20:31
MATINAS BIOPHARMA HOLDINGS INC <MTNB.A>: MAXIM GROUP RAISES TARGET PRICE TO $1 FROM $0.30
Reuters · 04/01 14:39
Weekly Report: what happened at MTNB last week (0325-0329)?
Weekly Report · 04/01 11:25
Matinas BioPharma Updates Presentation for Investor Outreach
TipRanks · 03/28 13:13
Matinas BioPharma Hldgs Q4 EPS $(0.03) Down From $(0.02) YoY
Benzinga · 03/28 03:42
MTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023
Matinas BioPharma Hldgs reported earnings per share of -3 cents for the first quarter. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports. The company has not reported any revenue.
Investorplace · 03/28 02:53
Matinas Biopharma GAAP EPS of -$0.11, revenue of $1.1M
Matinas BioPharma Holdings, Inc. Reports FY GAAP EPS of -$0.11, revenue of $1.1M (-65.5% Y/Y). The company believes its cash position is sufficient to fund planned operations through the third quarter of 2024. Shares of Matinas Biopharma fall 2.8%.
Seeking Alpha · 03/27 20:46
Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY
Revenue for 2023 was $1.1 million, compared to $3.2 million for 2022. The Company believes its cash position is sufficient to fund planned operations through the third quarter of 2024. Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million.
Benzinga · 03/27 20:34
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Barchart · 03/27 15:05
Matinas BioPharma’s LNC Technology Promises Safer Chemotherapy
TipRanks · 03/25 12:22
Weekly Report: what happened at MTNB last week (0318-0322)?
Weekly Report · 03/25 11:28
Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?
Matinas BioPharma Holdings Inc announced a complete clinical response in three patients with invasive fusarium infection. The patients were treated with MAT2203, Matinas’ oral formulation of antifungal amphotericin B. All three patients were enrolled in the company’s Compassionate/Expanded Use Access Program.
Benzinga · 03/22 14:37
More
Webull provides a variety of real-time MTNB stock news. You can receive the latest news about Matinas Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About MTNB
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.